By physician referral or invitation only

Effect of Vedolizumab and Tofacitinib Combination Therapy in Adults with Moderately to Severely Active Ulcerative Colitis

To determine the effect of dual targeted therapy with an anti-integrin (vedolizumab [VDZ]) and a Janus kinase (JAK) inhibitor (tofacitinib [TOF]) on clinical remission.

Age & Gender

18 years ~ 65 years
Male, Female, Gender Inclusive

Contact the Team

Location

Thank you for your interest, but this study is recruiting by invitation only.

North Carolina (Statewide)

Additional Study Information

Principal Investigator

Edward Barnes
Medicine-Gastroenterology

Study Type

Clinical or Medical
Interventional

Study Topics

Stomach, Digestion and Gut Health

IRB Number

24-0177

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.